Facebook link Linked In link You Tube link
  • FOCIS2016683x292Banner

    FOCIS 2016

    Save the date for FOCIS 2016 in Boston!  Learn more.

  • 2016AdvCourseSunglasses

    2016 Advanced Course

    Get a clinical spin on major topics of cellular and molecular immunology in a relaxed, winter getaway setting. Registration opens October 15!

  • Collaboration2015

    Strong Collaborations

    In the world of interdisciplinary immunology, collaboration is key. Meet with Key Opinion Leaders and peers from around the world by attending a FOCIS 2016.

  • Education2015

    Share Your Science

    Attendees from around the globe share their research and advance their careers. See their work

  • Industry2015

    Industry Partnership

    FOCIS provides a plethora of opportunities for industry to interact with immunology experts from around the world. Learn more.

News & Information


International Progreffe Foundation Doctoral/Postdoctoral Position

You're invited to apply for the Doctoral/Postdoctoral Position at the INSERM UMR-1064!

In 2011, the INSERM UMR 1064-Center for Research in Transplantation and Immunology/ITUN in Nantes, France launched an International Progreffe Foundation Program for doctoral/postdoctoral positions that is funded by the Progreffe Foundation.  A call is open for one doctoral fellowship in 2015. This Program aims to recruit a highly-motivated student to work with a young investigator of our Center. The PhD position will cover 3 year salary and will end with the presentation of a thesis and the delivery of a PhD diploma by the University of Nantes. Research activity and training will be in a strong research environment, with participations to at least one national or international meeting per year.


Immunology Catalyst Sabbatical Program at GSK

You're invited to apply for the Elion and Black Immunology Catalyst Sabbatical Program at GSK!

GSK is a global pharmaceutical company with a portfolio of innovative medicines and vaccines. Cutting edge immunology research, both in house and through collaboration underpins the discovery of new medicines for many of our disease areas, such as autoimmunity, cancer, metabolic disease, infection and respiratory disease http://www.gsk.com/en-gb/research/. To take Industry-Academic collaboration in immunology to the next level, GSK is launching a new and unique model of sabbatical-based collaboration, designed to drive major breakthroughs in applied immunology and broaden scientific insight.


All Articles...




FOCIS ePub Header

October 1, 2015 

EditorAndrew H. Lichtman, MD, PhD, Brigham & Women's Hospital
Editorial Board: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute | Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital

Highlights from Recent Literature

Regulating the Regulators: Shutting Down Regulatory T Cells with GARP-TGFβ1 Antibodies

Research paper: Julia Cuende et al. Monoclonal antibodies against GARP/TGFβ-1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Science Translational Medicine (2015) 7, 274ra18

Regulatory T cells (Treg) play critical roles in initiating and maintaining self tolerance but they can also interfere with tumor immunity and permit the persistence of chronic infections. One of the mechanisms by which Treg suppress other T cells is by presenting inactive TGFβ1 on the cell surface that becomes activated to immunosuppressive active TGFβ1 by unknown mechanisms. The authors demonstrate that the protein GARP plays a key role in TGFβ1 activation and that a monoclonal antibody that blocks this conversion inhibits Treg function.


Highlights from Clinical Immunology, Official Journal of FOCIS

B Cells and GCs in EAE

A review of Batoulis H. et al. “Central nervous system infiltrates are characterized by features of ongoing B cell-related immune activity in MP4-induced experimental autoimmune encephalomyelitis.” Clinical Immunology. (2015) 158, 47–58

B cell aggregates and perhaps tertiary lymphoid organs (TLOs) form in the meninges of multiple sclerosis (MS) patients, and these have been correlated with more aggressive disease. Nonetheless, the contribution of B cells, antibodies, and TLOs to MS is poorly understood. Experimental autoimmune encephalomyelitis (EAE) is a demyelinating disease of mice that is widely used as model of human MS. EAE is induced by immunization with myelin proteins and strong adjuvant, but the disease is usually helper T cell dependent. The authors have previously described a B cell-dependent variation of the EAE model, induced by immunization of C57BL/6 mice with MP4, a fusion protein of myelin basic protein (MBP) and parts of proteolipid protein (PLP). In this report, the authors' goal was to determine the function and disease impact of B ell infiltrates in the CNS in MP4-EAE.


Human Immunophenotyping Update

Immunophenotyping of Human NK Cells 

Catherine A. Blish, MD, PhD, Stanford University School of Medicine

Natural killer (NK) cells are innate lymphocytes that can rapidly respond to tumor or infected cells by killing (cytolysis) or by secreting cytokines. Unlike adaptive T and B lymphocytes that somatically rearrange antigen-specific receptors, NK cells express a variety of germline-encoded activating and inhibitory receptors on their cell surface. These receptors include the killer immunoglobulin-like receptors (KIR), C-type-lectin-like receptors (for example, NKG2A, NKG2C, and NKG2D), leukocyte immunoglobulin-like receptor subfamily b member 1 (LILRB1, also known as ILT-2 and CD85j), natural cytotoxicity receptors (NCRs, including NKp30, NKp44, NKp46, and NKp80), and signaling lymphocyte activation molecule (SLAM) family receptors (for example, 2B4, NTB-A). NK cells also express a variety of adhesion molecules such as CD2 and DNAM-1 that influence their function. These receptors allow NK cells to recognize ‘altered self’ on virus-infected, malignant or stressed cells.


Developments in Basic Immunology and Novel Therapies

B Cell Depletion Therapy For Autoimmune and Inflammatory Diseases

Shiv Pillai, PhD, Ragon Institute of MGH, MIT and Harvard; Harvard Medical School

B cell depletion using a monoclonal antibody to CD20, a B cell surface protein whose function remains poorly defined, was first conceived of as a therapeutic strategy to treat B cell lymphomas and chronic lymphocytic leukemia. Although this approach is still utilized for the treatment of B cell malignancies, B cell depletion has since emerged as a powerful way to treat a number of autoimmune and inflammatory conditions, including certain disorders that are generally believed to be caused by T cells. The initial anti-CD20 antibody used for therapy was a chimeric antibody called Rituximab. Rituximab remains the major B cell depleting reagent in clinical use today. The success of Rituximab therapy has spawned the generation of a number of newer therapeutics that also target B cells.


Selected Recent Clinical Trial Results
  • Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy
  • Effects Of High-dose Oral Insulin on Immune Responses in Children at High Risk for Type 1 Diabetes: The Pre-point Randomized Clinical Trial
  • Mongersen, an Oral Smad7 Antisense Oligonucleotide, and Crohn's Disease




Thank you to the 2013 FOCIS Corporate Council:

Amgen 4 Blue      Beckman      CelgeneLogo      genentech color